The DOI matches its Crossref record; 123 of the 123 references it cites were found in a registry or an index.
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Open accessAbstract
Changes in classical and nonclassical HLA class I as well as HLA class II antigens have been identified in malignant lesions. These changes, which are described in this review are believed to play a major role in the clinical course of the disease since both HLA class I and class II antigens are critical to the interaction between tumor cells and components of both innate and adaptive immune system. Abnormalities in HLA antigen expression in malignant cells, which range in frequency from 0–90%, are caused by distinct mechanisms. They include defects in β2-microglobulin (β2m) synthesis, loss of the gene(s) encoding HLA antigen heavy chain(s), mutations, which inhibit HLA antigen heavy chain transcription or translation, defects in the regulatory mechanisms, which control HLA antigen expression and/or abnormalities in one or more of the antigen processing, machinery (APM) components. More recently, epigenetic events associated with tumor development and progression have been found to underlie changes in HLA antigen, APM component, costimulatory molecule and tumor antigen (TA) expression in malignant cells. The types of epigenetic modifications that may occur in normal and malignant cells as well as their role in changes in HLA antigen expression by malignant cells have been reviewed. The epigenetic events associated with alterations in HLA antigen expression may be clinically relevant as, in some cases, they have been shown to impair the recognition of tumor cells by components of the adaptive immune system. The functional relevance and potential clinical significance of these epigenetic alterations have been addressed. Finally, unlike genetic alterations, epigenetic modifications can, in some cases, be reversed with pharmacologic agents that induce DNA hypomethylation or inhibit histone deacetylation. Therefore, strategies to overcome epigenetic modifications underlying changes in HLA antigen expression in malignant cells have been discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Induction of DNA methylation and gene silencing by short interfering RNAs in human cells
Kawasaki, H., & Taira, K. (2004) · Nature · doi:10.1038/nature02889 · Cited by 367
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The fundamental role of epigenetic events in cancer
Jones, P. A., & Baylin, S. B. (2002) · Nature Reviews Genetics · doi:10.1038/nrg816 · Cited by 5,648
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Gene Silencing in Cancer in Association with Promoter Hypermethylation
Herman, J. G., & Baylin, S. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023075 · Cited by 3,422
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557
The history of cancer epigenetics
Feinberg, A. P., & Tycko, B. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1279 · Cited by 2,344
Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions
Shogren-Knaak, M., Ishii, H., Sun, J.-M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006) · Science · doi:10.1126/science.1124000 · Cited by 1,873
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
Calin, G. A., Liu, C.-G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404432101 · Cited by 1,285
Phylogenetic Shadowing and Computational Identification of Human microRNA Genes
Berezikov, E., Guryev, V., van de Belt, J., Wienholds, E., Plasterk, R. H. A., & Cuppen, E. (2005) · Cell · doi:10.1016/j.cell.2004.12.031 · Cited by 1,270
Bedford, M. T., & Richard, S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.003 · Cited by 1,099
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,074
Heterochromatin and Epigenetic Control of Gene Expression
Grewal, S. I. S., & Moazed, D. (2003) · Science · doi:10.1126/science.1086887 · Cited by 1,065
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Scanlan., M. J., Gure., A. O., Jungbluth., A. A., Old., L. J., & Chen., Y. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18803.x · Cited by 873
Regulation of p53 activity through lysine methylation
Chuikov, S., Kurash, J. K., Wilson, J. R., Xiao, B., Justin, N., Ivanov, G. S., McKinney, K., Tempst, P., Prives, C., Gamblin, S. J., et al. (2004) · Nature · doi:10.1038/nature03117 · Cited by 816
Issa, J.-P. J., Garcia-Manero, G., Giles, F. J., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C. S., Cortes, J., et al. (2004) · Blood · doi:10.1182/blood-2003-03-0687 · Cited by 809
Di Croce, L., Raker, V. A., Corsaro, M., Fazi, F., Fanelli, M., Faretta, M., Fuks, F., Coco, F. L., Kouzarides, T., Nervi, C., et al. (2002) · Science · doi:10.1126/science.1065173 · Cited by 787
Histone lysine methylation: a signature for chromatin function
Sims, R. J., Nishioka, K., & Reinberg, D. (2003) · Trends in Genetics · doi:10.1016/j.tig.2003.09.007 · Cited by 691
Tumor antigen-specific T helper cells in cancer immunity and immunotherapy
Knutson, K. L., & Disis, M. L. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0653-2 · Cited by 682
An epigenetic road map for histone lysine methylation
Lachner, M., O'Sullivan, R. J., & Jenuwein, T. (2003) · Journal of Cell Science · doi:10.1242/jcs.00493 · Cited by 630
Wijermans, P., Lübbert, M., Verhoef, G., Bosly, A., Ravoet, C., Andre, M., & Ferrant, A. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.956 · Cited by 567
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Daskalakis, M., Nguyen, T. T., Nguyen, C., Guldberg, P., Köhler, G., Wijermans, P., Jones, P. A., & Lübbert, M. (2002) · Blood · doi:10.1182/blood.v100.8.2957 · Cited by 514
Dnmt3a binds deacetylases and is recruited by a sequence‐specific repressor to silence transcription
Fuks, F., Burgers, W. A., Godin, N., Kasai, M., & Kouzarides, T. (2001) · The EMBO Journal · doi:10.1093/emboj/20.10.2536 · Cited by 473
Regulation of MHC class II gene expression by the class II transactivator
Reith, W., LeibundGut-Landmann, S., & Waldburger, J.-M. (2005) · Nature Reviews Immunology · doi:10.1038/nri1708 · Cited by 462
Antigen-processing machinery breakdown and tumor growth
Seliger, B., Maeurer, M. J., & Ferrone, S. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01692-3 · Cited by 459
Self-citationRelevance of DNA methylation in the management of cancer
Esteller, M. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01115-x · Cited by 329
Transcriptional Repression by Blimp-1 (PRDI-BF1) Involves Recruitment of Histone Deacetylase
Yu, J., Angelin-Duclos, C., Greenwood, J., Liao, J., & Calame, K. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2592-2603.2000 · Cited by 327
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., & Weller, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1627 · Cited by 305
Activation of MHC Class I, II, and CD40 Gene Expression by Histone Deacetylase Inhibitors
Magner, W. J., Kazim, A. L., Stewart, C., Romano, M. A., Catalano, G., Grande, C., Keiser, N., Santaniello, F., & Tomasi, T. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.7017 · Cited by 294
Silence from within: Endogenous siRNAs and miRNAs
Sontheimer, E. J., & Carthew, R. W. (2005) · Cell · doi:10.1016/j.cell.2005.06.030 · Cited by 291
Epigenetics provides a new generation of oncogenes and tumour-suppressor genes
Esteller, M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602918 · Cited by 284
Histone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
How do CD4+CD25+ regulatory T cells control autoimmunity?
Bluestone, J. A., & Tang, Q. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.09.002 · Cited by 245
Jinushi, M., Takehara, T., Tatsumi, T., Kanto, T., Groh, V., Spies, T., Kimura, R., Miyagi, T., Mochizuki, K., Sasaki, Y., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.10966 · Cited by 244
Serrano, A., Tanzarella, S., Lionello, I., Mendez, R., Traversari, C., Ruiz-Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 235
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Pishchik, V., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0669 · Cited by 227
Sigalotti, L., Fratta, E., Coral, S., Tanzarella, S., Danielli, R., Colizzi, F., Fonsatti, E., Traversari, C., Altomonte, M., & Maio, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1442 · Cited by 217
Chuang, J. C., Yoo, C. B., Kwan, J. M., Li, T. W. H., Liang, G., Yang, A. S., & Jones, P. A. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0172 · Cited by 210
The Role of the RNAi Machinery in Heterochromatin Formation
Wassenegger, M. (2005) · Cell · doi:10.1016/j.cell.2005.06.034 · Cited by 208
Nie, Y. (2001) · Carcinogenesis · doi:10.1093/carcin/22.10.1615 · Cited by 202
Khan, A. N. H., Gregorie, C. J., & Tomasi, T. B. (2008) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0402-4 · Cited by 197
Epigenetic regulation of MHC-II and CIITA genes
Wright, K. L., & Ting, J. P.-Y. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.07.007 · Cited by 194
Soluble HLA-G: Are they clinically relevant?
Pistoia, V., Morandi, F., Wang, X., & Ferrone, S. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.004 · Cited by 181
Self-citationMalmberg, K.-J., Levitsky, V., Norell, H., Matos, C. T. D., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15564 · Cited by 180
Johnsen, A. K., Templeton, D. J., Sy, M.-S., & Harding, C. V. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4224 · Cited by 173
Towards the Human Cancer Epigenome: A First Draft of Histone Modifications
Fraga, M. F., & Esteller, M. (2005) · Cell Cycle · doi:10.4161/cc.4.10.2113 · Cited by 171
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 165
Ye, S.-R., Yang, H., Li, K., Dong, D.-D., Lin, X.-M., & Yie, S.-M. (2007) · Modern Pathology · doi:10.1038/modpathol.3800751 · Cited by 159
Malmberg, K., Levitsky, V., Norell, H., de Matos, C. T., Carlsten, M., Schedvins, K., Rabbani, H., Moretta, A., Söderström, K., Levitskaya, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215564 · Cited by 151
Pierson, B., & Miller, J. S. (1996) · Blood · doi:10.1182/blood.v88.6.2279.bloodjournal8862279 · Cited by 141
Moretta, L., Bottino, C., Pende, D., Vitale, M., Mingari, M., & Moretta, A. (2005) · Immunology Letters · doi:10.1016/j.imlet.2005.07.004 · Cited by 140
Guo, Z. S., Hong, J. A., Irvine, K. R., Chen, G. A., Spiess, P. J., Liu, Y., Zeng, G., Wunderlich, J. R., Nguyen, D. M., Restifo, N. P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3020 · Cited by 138
Lucas, D. M., Davis, M. E., Parthun, M. R., Mone, A. P., Kitada, S., Cunningham, K. D., Flax, E. L., Wickham, J., Reed, J. C., Byrd, J. C., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403388 · Cited by 136
Fonsatti, E., Nicolay, H. J. M., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F. M., & Maio, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3091 · Cited by 135
Gollob, J., Sciambi, C. J., Peterson, B. L., Richmond, T. M., Thoreson, M., Moran, K., Dressman, H. K., Jelínek, J., & Issa, J. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0883 · Cited by 133
The role of HLA-G in human pregnancy
Hunt, J. S., Langat, D. K., McIntire, R. H., & Morales, P. J. (2006) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-4-s1-s10 · Cited by 132
Epigenetic regulation of immune escape genes in cancer
Tomasi, T. B., Magner, W. J., & Khan, A. N. H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0164-4 · Cited by 132
Animal models of tumor immunity, immunotherapy and cancer vaccines
Ostrand‐Rosenberg, S. (2004) · Current Opinion in Immunology · doi:10.1016/j.coi.2004.01.003 · Cited by 123
DNA Methylation and Demethylation as Targets for Anticancer Therapy
Szyf, M. (2005) · Biochemistry (Moscow) · doi:10.1007/s10541-005-0147-7 · Cited by 121
Demanet, C. J., Mulder, A., Deneys, V., Worsham, M. J., Maes, P., Claas, F. H. J., & Ferrone, S. (2003) · Blood · doi:10.1182/blood-2003-07-2500 · Cited by 118
Self-citationChang, C., Campoli, M. R., & Ferrone, S. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)93006-6 · Cited by 117
Self-citationImmune selective pressure and HLA class I antigen defects in malignant lesions
Chang, C., & Ferrone, S. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0183-1 · Cited by 117
Self-citationMorandi, F., Levreri, I., Bocca, P., Galleni, B., Raffaghello, L., Ferrone, S., Prigione, I., & Pistoia, V. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4588 · Cited by 113
Self-citationMHC antigens in human melanomas.
Dj, R., Mattijssen, V., Broecker, E.-B., & Ferrone, S. (1991) · PubMed · Cited by 111
Self-citationSatoh, A., Toyota, M., Ikeda, H., Morimoto, Y., Akino, K., Mita, H., Suzuki, H., Sasaki, Y., Kanaseki, T., Takamura, Y., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208144 · Cited by 105
Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses
Rouas‐Freiss, N., Moreau, P., Menier, C., LeMaoult, J., & Carosella, E. D. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.003 · Cited by 104
HLA-G expression in human ovarian carcinoma counteracts NK cell function
Lin, A., Yan, W., Xu, H., Gan, M. F., Cai, J., Zhu, M., & Zhou, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm356 · Cited by 101
Rodríguez, T., Méndez, R., Campo, A. D., Jiménez, P., Aptsiauri, N., Garrido, F., & Ruiz‐Cabello, F. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-34 · Cited by 98
Defective death receptor signaling as a cause of tumor immune escape
French, L. E., & Tschopp, J. (2002) · Seminars in Cancer Biology · doi:10.1006/scbi.2001.0405 · Cited by 93
Li, H., & Wu, X. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.130 · Cited by 89
Regulatory T cells and tumor immunity
Chattopadhyay, S., Chakraborty, N. G., & Mukherji, B. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0699-9 · Cited by 86
Eramo, A., D, R. P. M., Lotti, F., Sette, G., Patti, M., Bartucci, M., Ricci‐Vitiani, L., Signore, M., Stassi, G., Larocca, L. M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1724 · Cited by 84
Bovenzi, V., Lê, N. L. O., Côté, S., Sinnett, D., Momparler, L. F., & Momparler, R. L. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199906000-00007 · Cited by 82
Sigalotti, L., Altomonte, M., Colizzi, F., Degan, M., Rupolo, M., Zagonel, V., Pinto, A., Gattei, V., & Maio, M. (2003) · Blood · doi:10.1182/blood-2002-11-3458 · Cited by 79
Natoni, F., Diolordi, L., Santoni, C., & Montani, M. S. G. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2005.07.003 · Cited by 79
Moore, P. S., Barbi, S., Donadelli, M., Costanzo, C., Bassi, C., Palmieri, M., & Scarpa, A. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.07.001 · Cited by 77
Chou, S., Khan, A. N. H., Magner, W. J., & Tomasi, T. B. (2005) · International Immunology · doi:10.1093/intimm/dxh326 · Cited by 74
van den Elsen, P. J., van der Stoep, N., Viëtor, H. E., Wilson, L., van Zutphen, M., & Gobin, S. J. P. (2000) · Human Immunology · doi:10.1016/s0198-8859(00)00159-2 · Cited by 72
Epigenetic targets for immune intervention in human malignancies
Maio, M., Coral, S., Fratta, E., Altomonte, M., & Sigalotti, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206956 · Cited by 71
Epigenetic Control of the Immune Escape Mechanisms in Malignant Carcinomas
Setiadi, A., David, M. D., Seipp, R. P., Hartikainen, J. A., Gopaul, R., & Jefferies, W. A. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01547-07 · Cited by 71
Ghosh, N., Győry, I., Wright, G. M., Wood, J., & Wright, K. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100862200 · Cited by 68
Sebti, Y., Maux, A. L., Gros, F., de Guibert, S., Pangault, C., Rouas‐Freiss, N., Bernard, M., & Amiot, L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06647.x · Cited by 68
van der Stoep, N., Biesta, P. J., Quinten, E., & van den Elsen, P. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1623 · Cited by 66
Campoli, M. R., Ferrone, S., Zea, A. H., Rodríguez, P. C., & Ochoa, A. C. (2007) · Springer eBooks · doi:10.1007/0-387-27545-2_3 · Cited by 64
Self-citationSingh, N. P., Yolcu, E. S., Taylor, D. D., Gerçel-Taylor, Ç., Metzinger, D. S., Dreisbach, S. K., & Shirwan, H. (2003) · PubMed · Cited by 60
Clinical and biological significance of HLA-G expression in ovarian cancer
Sheu, J. J., & Shih, I. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.012 · Cited by 58
Wischhusen, J., Waschbisch, A., & Wiendl, H. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.07.005 · Cited by 58
Senescence and epigenetic dysregulation in cancer
Neumeister, P., Albanese, C., Balent, B., Greally, J., & Pestell, R. G. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(02)00079-1 · Cited by 56
Antigen processing and presentation
Cresswell, P. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00320.x · Cited by 56
Morimoto, Y., Toyota, M., Satoh, A., Murai, M., Mita, H., Suzuki, H., Takamura, Y., Ikeda, H., Ishida, T., Sato, N., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601602 · Cited by 53
Verfaillie, C. M., Kay, N. E., Miller, W., & McGlave, P. B. (1990) · Blood · doi:10.1182/blood.v76.2.401.401 · Cited by 52
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Flørenes, V. A., Skrede, M. L., Jørgensen, K., & Nesland, J. M. (2004) · Melanoma Research · doi:10.1097/01.cmr.0000129576.49313.26 · Cited by 52
Biological Implications of HLA‐DR Expression in Tumours
Cabrera, T., Ruiz‐Cabello, F., & Garrido, F. (1995) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.1995.tb03584.x · Cited by 50
Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
Altomonte, M., Fonsatti, E., Visintin, A., & Maio, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206960 · Cited by 48
Invariant chain expression in colon neoplasms
Jiang, Z., Xu, M., Savas, L., LeClair, P., & Banner, B. F. (1999) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s004280050391 · Cited by 48
Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., Pezzani, L., Fratta, E., Fonsatti, E., Giacomo, A. M. D., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20540 · Cited by 48
HLA-G in melanoma: can the current controversies be solved?
Chang, C., & Ferrone, S. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(03)00027-0 · Cited by 48
Self-citationMHC class II molecules in tumour immunology: Prognostic marker and target for immune modulation
Chamuleau, M. E. D., Ossenkoppele, G. J., & van de Loosdrecht, A. A. (2006) · Immunobiology · doi:10.1016/j.imbio.2006.05.005 · Cited by 47
Lozupone, F., Rivoltini, L., Luciani, F., Venditti, M., Lugini, L., Cova, A., Squarcina, P., Parmiani, G., Belardelli, F., & Fais, S. (2003) · European Journal of Immunology · doi:10.1002/immu.200310032 · Cited by 47
On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases
Bernsen, M. R., Håkansson, L., Gustafsson, B., Krysander, L., Rettrup, B., Ruiter, D., & Håkansson, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600703 · Cited by 46
Methylation‐regulated expression of HLA class I antigens in melanoma
Fonsatti, E., Sigalotti, L., Coral, S., Colizzi, F., Altomonte, M., & Maio, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.11077 · Cited by 45
Kanaseki, T., Ikeda, H., Takamura, Y., Toyota, M., Hirohashi, Y., Tokino, T., Himi, T., & Sato, N. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4980 · Cited by 44
Activation of Natural Killer Cells: Underlying Molecular Mechanisms Revealed
Backström, E., Kristensson, K., & Ljunggren, H. (2004) · Scandinavian Journal of Immunology · doi:10.1111/j.0300-9475.2004.01475.x · Cited by 44
An epigenetically altered tumor cell vaccine
Khan, A. N., Magner, W., & Tomasi, T. (2004) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0513-0 · Cited by 42
Chang, C., & Ferrone, S. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.001 · Cited by 36
Self-citationÖğretmen, B., McCauley, M. D., & Safa, A. R. (1998) · Biochemistry · doi:10.1021/bi980573c · Cited by 33
Epigenetic remodelling of DNA in cancer.
Lettini, A. A., Guidoboni, M., Fonsatti, E., Anzalone, L., Cortini, E., & Maio, M. (2007) · PubMed · doi:10.14670/hh-22.1413 · Cited by 32
Chiorean, E. G., Dylla, S. J., Olsen, K., Lenvik, T. R., Soignier, Y., & Miller, J. S. (2003) · Blood · doi:10.1182/blood-2002-04-1172 · Cited by 30
Campoli, M. R., Chang, C., Oldford, S. A., Edgecombe, A. D., Drover, S., & Ferrone, S. (2004) · Breast Disease · doi:10.3233/bd-2004-20112 · Cited by 30
Self-citationRegulation of MHC class II expression in glioma cells by class II transactivator (CIITA)
Takamura, Y., Ikeda, H., Kanaseki, T., Toyota, M., Tokino, T., Imai, K., Houkin, K., & Sato, N. (2003) · Glia · doi:10.1002/glia.10343 · Cited by 29
Immunoepigenetics: the unseen side of cancer immunoediting
Germenis, A. E., & Karanikas, V. (2006) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100006 · Cited by 24
5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story
Coral, S., Sigalotti, L., Covre, A., Nicolay, H. J. M., Natali, P. G., & Maio, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2986 · Cited by 23
Chaperoning Antigen Presentation by MHC Class II Molecules and Their Role in Oncogenesis
Marsman, M., Jordens, I., Griekspoor, A., & Neefjes, J. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)93004-2 · Cited by 16
Tamori, Y., Tan, X., Nakagawa, K., Takai, E., Akagi, J., Kageshita, T., Egami, H., & Ogawa, M. (2005) · Oncology Reports · doi:10.3892/or.14.4.873 · Cited by 16
Understanding the response to immunotherapy in humans
Wang, E., Panelli, M. C., & Marincola, F. M. (2005) · Springer Seminars in Immunopathology · doi:10.1007/s00281-004-0198-7 · Cited by 11
Immune Escape: Tumor induced immune suppression and immune escape: Mechanisms and Possible Solutions
Whiteside, T. L., Campoli, M. R., & Ferrone, S. (2005) · Springer eBooks · doi:10.1007/1-4020-3623-x_3 · Cited by 9
Self-citation
Cited by
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Beatty, G. L., & Gladney, W. L. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1860 · Cited by 1,078
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Self-citation
Metadata
- Authors
- Campoli, M., & Ferrone, S.
- Venue
- Oncogene
- Published
- 2008-10-06
- Volume
- 27
- Issue
- 45
- Pages
- 5869-5885
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2068116723
- Cited by
- 404
- References
- 123
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.